Search clinical trials for: SLV341

Total 161 results

Solvay Pharmaceuticals
Quintiles, Inc.

Terminated

First in Man Study With SLV341

Diabetes

United Kingdom
Abbott Products
Quintiles, Inc.

Terminated

First in Man Study With SLV342

Pharmacokinetics

United Kingdom
Abbott Products

Completed

14-C ADME (Absorption, Disposition, Metabolism and Excretion) Study in Man

Healthy Subjects

Netherlands
Solvay Pharmaceuticals

Completed

Interaction Study SLV337/Simvastatin

Type 2 Diabetes Mellitus

United Kingdom
Abbott

Completed

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

Hypogonadal Males

United States
Abbott Products
Quintiles, Inc.

Terminated

A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.

Traumatic Brain Injury

United States, Israel, Italy, Spain
Solvay Pharmaceuticals

Completed

Safety and Tolerability of the First IV Dosing of SLV338 in Healthy Volunteers

Healthy

United Kingdom
Solvay Pharmaceuticals

Terminated

Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

Czech Republic, Denmark, Hungary, Latvia, Poland, Russian Federation, Sweden
Abbott
Quintiles, Inc.

Terminated

This is a Single Ascending Dose Tolerance Study

Cognition Disorders

United Kingdom
Heidelberg University

Completed

NK-1 Antagonism of SLV317 in Humans

Healthy

Germany
Abbott

Completed

A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia

Schizophrenia

United States
Solvay Pharmaceuticals
Quintiles, Inc.

Terminated

Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function

Congestive Heart Failure

United States, Argentina, Belgium, Czech Republic, Former Serbia and Montenegro, Germany, Poland, Russian Federation, South Africa, Spain
Abbott Products
Quintiles, Inc.

Completed

A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes

Type 2 Diabetes

Bulgaria, Poland, South Africa
Solvay Pharmaceuticals

Completed

Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease

Parkinson's Disease

Bulgaria, Malta, Serbia
AbbVie

Completed

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms (CisCP)

Chronic Pancreatitis

United States
AbbVie

Withdrawn

Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer

Exocrine Pancreatic Insufficiency (EPI)
Solvay Pharmaceuticals

Terminated

Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure

Acute Decompensated Heart Failure; Renal Dysfunction

United States, Canada, Chile, Denmark, France, Germany, Italy, Poland, Romania, Russian Federation, Ukraine
Solvay Pharmaceuticals

Completed

Study to Evaluate Cardiac Hemodynamics and Safety of SLV320 in Subjects With Congestive Heart Failure

Congestive Heart Failure

Germany
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Leukemia

United States
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Lymphoproliferative Disorders

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Recurrent Glioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Previously Treated Myelodysplastic Syndromes | Recurrent Adult Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Blastic Phase Chronic Myelogenous Leukemia and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid... and other conditions

United States
National Cancer Institute (NCI)

Completed

Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

Malignant Neoplasm | Hepatic Complications

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

Lymphoma, B-Cell

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); GlaxoSmithKline; Millennium Pharmaceuticals,...

Terminated

Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Children With Advanced Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia

Childhood Acute Promyelocytic Leukemia (M3) | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

Waldenström Macroglobulinemia

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult... and other conditions

United States
Mayo Clinic

Completed

Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States
Abbott Biologicals

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season

Prophylaxis of Influenza

Germany
M.D. Anderson Cancer Center

Completed

Study of Erlotinib in Combination With Bortezomib

Advanced Cancer

United States
National Cancer Institute (NCI)

Terminated

Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Terminated

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States

Search clinical trials for: SLV341

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations